Systemic administration of fibroblast growth factor-2 (FGF2) reduces BACE1 expression and amyloid pathology in APP23 mice

Neurobiology of Aging

Volumn 36, Issue 2, 2015, Pages 821-831

  Katsouri, Loukia ^a   Ashraf, Azhaar ^a   Birch, Amy M ^a   Lee, Kevin K L ^a   Mirzaei, Nazanin ^a   Sastre, Magdalena ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Alzheimer's disease; Amyloid ; BACE1; Cell differentiation; Growth factor; Inflammation

Indexed keywords

AMYLOID BETA PROTEIN; BETA SECRETASE 1; FIBROBLAST GROWTH FACTOR 2; INDUCIBLE NITRIC OXIDE SYNTHASE; ASPARTIC PROTEINASE; BACE1 PROTEIN, MOUSE; SECRETASE; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; AUTOPSY; BRAIN LEVEL; CELL COUNT; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DENTATE GYRUS; DRUG EFFECT; FEMALE; HUMAN; HUMAN TISSUE; MALE; MOUSE; NEUROBLAST; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SPATIAL MEMORY; TREATMENT DURATION; ANIMAL; BRAIN; CELL LINE; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PATHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; BRAIN; CELL LINE; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MICE, TRANSGENIC; TAU PROTEINS; TRANSCRIPTION, GENETIC;

EID: 84922789261     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.10.004     Document Type: Article

References (66)

1. Almeida R.D., Manadas B.J., Melo C.V., Gomes J.R., Mendes C.S., Graos M.M., Carvalho R.F., Carvalho A.P., Duarte C.B. Neuroprotection by BDNF against glutamate-induced apoptotic cell death is mediated by ERK and PI3-kinase pathways. Cell Death Differ. 2005, 12:1329-1343.
2. Bäckman C., Rose G.M., Hoffer B.J., Henry M.A., Bartus R.T., Friden P., Granholm A. Systemic administration of a nerve growth factor conjugate reverses age-related cognitive dysfunction and prevents cholinergic neuron atrophy. J.Neurosci. 1996, 16:5437-5442.
3. Bikfalvi A., Klein S., Pintucci G., Rifkin D.B. Biological roles of fibroblast growth Factor-2. Endocr. Rev. 1997, 18:26-45.
4. Bovolenta R., Zucchini S., Paradiso B., Rodi D., Merigo F., Navarro Mora G., Osculati F., Berto E., Marconi P., Marzola A., Fabene P.F., Simonato M. Hippocampal FGF-2 and BDNF overexpression attenuates epileptogenesis-associated neuroinflammation and reduces spontaneous recurrent seizures. J.Neuroinflammation 2010, 7:81.
5. Bürger S., Noack M., Kirazov L.P., Kirazov E.P., Naydenov C.L., Kouznetsova E., Yafai Y., Schliebs R. Vascular endothelial growth factor (VEGF) affects processing of amyloid precursor protein and β-amyloidogenesis in brain slice cultures derived from transgenic Tg2576 mouse brain. Int. J. Dev. Neurosci. 2009, 27:517-523.
6. Carlson G.A., Borchelt D.R., Dake A., Turner S., Danielson V., Coffin J.D., Eckman C., Meiners J., Nilsen S.P., Younkin S.G., Hsiao K.K. Genetic modification of the phenotypes produced by amyloid precursor protein overexpression in transgenic mice. Hum. Mol. Genet. 1997, 6:1951-1959.
7. Citron M. Alzheimer's disease: strategies for disease modification. Nat. Rev. Drug Discov. 2010, 9:387-398.
8. Colasanti M., Di Pucchio T., Persichini T., Sogos V., Presta M., Lauro G.M. Inhibition of inducible nitric oxide synthase mRNA expression by basic fibroblast growth factor in human microglial cells. Neurosci. Lett. 1995, 195:45-48.
9. Cummings B.J., Su J.H., Cotman C.W. Neuritic involvement within bFGF immunopositive plaques of Alzheimer's disease. Exp. Neurol. 1993, 124:315-325.
10. Deguchi Y., Naito T., Yuge T., Furukawa A., Yamada S., Pardridge W.M., Kimura R. Blood-brain barrier transport of 125I-labeled basic fibroblast growth factor. Pharm. Res. 2000, 17:63-69.
11. Deguchi Y., Okutsu H., Okura T., Yamada S., Kimura R., Yuge T., Furukawa A., Morimoto K., Tachikawa M., Ohtsuki S., Hosoya K., Terasaki T. Internalization of basic fibroblast growth factor at the mouse blood-brain barrier involves perlecan, a heparan sulfate proteoglycan. J.Neurochem. 2002, 83:381-389.
12. Donahue J.E., Coffin J.D., Johanson C.E., Van Nostrand W.E., Vitek M.P., Blay E., Miller M.C., Monfils P., McMillan P.N., Stopa G.E. Effects of FGF-2 overexpression in the Dutch/Iowa APP transgenic mouse. FASEB J. 2008, 22:707.4.
13. Dono R., Texido G., Dussel R., Ehmke H., Zeller R. Impaired cerebral cortex development and blood pressure regulation in FGF-2-deficient mice. EMBO J. 1998, 17:4213-4225.
14. Encinas J.M., Michurina T.V., Peunova N., Park J.H., Tordo J., Peterson D.A., Fishell G., Koulakov A., Enikolopov G. Division-coupled astrocytic differentiation and age-related depletion of neural stem cells in the adult hippocampus. Cell Stem Cell 2011, 8:566-579.
15. Gomez-Nicola D., Suzzi S., Vargas-Caballero M., Fransen N.L., Al-Malki H., Cebrian-Silla A., Garcia-Verdugo J.M., Riecken K., Fehse B., Perry V.H. Temporal dynamics of hippocampal neurogenesis in chronic neurodegeneration. Brain 2014, 137:2312-2328.
16. Gómez-Pinilla F., Vu L., Cotman C.W. Regulation of astrocyte proliferation by FGF-2 and heparan sulfate invivo. J.Neurosci. 1995, 15:2021-2029.
17. Graham B., Richardson R. Early-life exposure to fibroblast growth factor-2 facilitates context-dependent long-term memory in developing rats. Behav. Neurosci. 2010, 124:337-345.
18. Gray C.W., Patel A.J. Induction of beta-amyloid precursor protein isoform mRNAs by bFGF in astrocytes. Neuroreport 1993, 4:811-814.
19. Imaizumi K., Iwata H., Yoshida S., Sun G., Okumura N., Shiosaka S. Coexistence of amyloid β-protein precursor and basic fibroblast growth factor in single cells of the rat parietal cortex, hippocampus and basal magnocellular nucleus. J.Chem. Neuroanat. 1993, 6:159-165.
20. Irmady K., Zechel S., Unsicker K. Fibroblast growth factor 2 regulates astrocyte differentiation in a region-specific manner in the hindbrain. Glia 2011, 59:708-719.
21. Ishiyama J., Saito H., Abe K. Epidermal growth factor and basic fibroblast growth factor promote the generation of long-term potentiation in the dentate gyrus of anaesthetized rats. Neurosci. Res. 1991, 12:403-411.
22. Jacobsen K.T., Adlerz L., Multhaup G., Iverfeldt K. Insulin-like growth factor-1 (IGF-1)-induced processing of amyloid-beta precursor protein (APP) and APP-like protein 2 is mediated by different metalloproteinases. J.Biol. Chem. 2010, 285:10223-10231.
23. Jin K., LaFevre-Bernt M., Sun Y., Chen S., Gafni J., Crippen D., Logvinova A., Ross C.A., Greenberg D.A., Ellerby L.M. FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's disease. Proc. Nat. Acad. Sci. U. S. A. 2005, 102:18189-18194.
24. Katsouri L., Parr C., Bogdanovic N., Willem M., Sastre M. PPARγ co-activator-1α (PGC-1α) reduces amyloid-β generation through a PPARγ-dependent mechanism. J.Alzheimers Dis. 2011, 25:151-162.
25. Katsouri L., Vizcaychipi M.P., McArthur S., Harrison I., Suárez-Calvet M., Lleo A., Lloyd D.G., Ma D., Sastre M. Prazosin, an α(1)-adrenoceptor antagonist, prevents memory deterioration in the APP23 transgenic mouse model of Alzheimer's disease. Neurobiol. Aging 2013, 34:1105-1115.
26. Kiyota T., Ingraham K.L., Jacobsen M.T., Xiong H., Ikezu T. FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer's disease and has therapeutic implications for neurocognitive disorders. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:E1339-E1348.
27. Larkin A.E., Fahey B., Gobbo O., Callaghan C.K., Cahill E., O'Mara S.M., Kelly Á.M. Blockade of NMDA receptors pre-training, but not post-training, impairs object displacement learning in the rat. Brain Res. 2008, 1199:126-132.
28. Liao S., Bodmer J., Pietras D., Azhar M., Doetschman T., Schultz J.J. Biological functions of the low and high molecular weight protein isoforms of fibroblast growth factor-2 in cardiovascular development and disease. Dev. Dyn. 2009, 238:249-264.
29. Matsuda S., Saito H., Nishiyama N. Effect of basic fibroblast growth factor on neurons cultured from various regions of postnatal rat brain. Brain Res. 1990, 520:310-316.
30. Nagahara A.H., Mateling M., Kovacs I., Wang L., Eggert S., Rockenstein E., Koo E.H., Masliah E., Tuszynski M.H. Early BDNF treatment ameliorates cell loss in the entorhinal cortex of APP transgenic mice. J.Neurosci. 2013, 33:15596-15602.
31. Nagahara A.H., Merrill D.A., Coppola G., Tsukada S., Schroeder B.E., Shaked G.M., Wang L., Blesch A., Kim A., Conner J.M., Rockenstein E., Chao M.V., Koo E.H., Geschwind D., Masliah E., Chiba A.A., Tuszynski M.H. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat. Med. 2009, 15:331-337.
32. Okada-Ban M., Thiery J.P., Jouanneau J. Fibroblast growth factor-2. Int. J. Biochem. Cell Biol. 2000, 32:263-267.
33. Ortega S., Ittmann M., Tsang S.H., Ehrlich M., Basilico C. Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:5672-5677.
34. Perry G., Richey P., Siedlak S.L., Galloway P., Kawai M., Cras P. Basic fibroblast growth factor binds to filamentous inclusions of neurodegenerative diseases. Brain Res. 1992, 579:350-352.
35. Pike C.J., Cummings B.J., Monzavi R., Cotman C.W. Beta-amyloid-induced changes in cultured astrocytes parallel reactive astrocytosis associated with senile plaques in Alzheimer's disease. Neuroscience 1994, 63:517-531.
36. Presta M., Andrés G., Leali D., Dell'Era P., Ronca R. Inflammatory cells and chemokines sustain FGF2-induced angiogenesis. Eur. Cytokine Netw. 2009, 20:39-50.
37. Puigserver P., Adelmant G., Wu Z., Fan M., Xu J., O'Malley B., Spiegelman B.M. Activation of PPARgamma coactivator-1 through transcription factor docking. Science 1999, 286:1368-1371.
38. Raballo R., Rhee J., Lyn-Cook R., Leckman J.F., Schwartz M.L., Vaccarino F.M. Basic fibroblast growth factor (Fgf2) is necessary for cell proliferation and neurogenesis in the developing cerebral cortex. J.Neurosci. 2000, 20:5012-5023.
39. Reuss B., von Bohlen und Halbach O. Fibroblast growth factors and their receptors in the central nervous system. Cell Tissue Res. 2003, 313:139-157.
40. Rossner S., Sastre M., Bourne K., Lichtenthaler S.F. Transcriptional and translational regulation of BACE1 expression-implications for Alzheimer's disease. Prog. Neurobiol. 2006, 79:95-111.
41. Sastre M., Dewachter I., Landreth G.E., Willson T.M., Klockgether T., van Leuven F., Heneka M.T. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J.Neurosci. 2003, 23:9796-9804.
42. Sastre M., Dewachter I., Rossner S., Bogdanovic N., Rosen E., Borghgraef P., Evert B.O., Dumitrescu-Ozimek L., Thal D.R., Landreth G., Walter J., Klockgether T., van Leuven F., Heneka M.T. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:443-448.
43. Sastre M., Ortega S., Basilico C., Levy E. Deficiency of basic fibroblast growth factor affects beta-amyloid plaque formation in transgenic mice. Soc. Neurosci. Abstr. 2000, 26. 276.6.
44. Shi J., Perry G., Berridge M.S., Aliev G., Siedlak S.L., Smith M.A., LaManna J.C., Friedland R.P. Labeling of cerebral amyloid beta deposits invivo using intranasal basic fibroblast growth factor and serum amyloid P component in mice. J.Nucl. Med. 2002, 43:1044-1051.
45. Stachowiak M.K., Moffett J., Maher P., Tocholski J., Stachowiak E.K. Growth factor regulation of cell growth and proliferation in the nervous system. A new intracrine nuclear mechanism. Mol. Neurobiol. 1997, 15:257-283.
46. Steinert J.R., Chernova T., Forsythe I.D. Nitric oxide signaling in brain function, dysfunction, and dementia. Neuroscientist 2010, 16:435-452.
47. Stopa E.G., Berzin T.M., Kim S., Song P., Kuo-LeBlanc V., Rodriguez-Wolf M., Baird A., Johanson C.E. Human choroid plexus growth factors: what are the implications for CSF dynamics in Alzheimer's disease?. Exp. Neurol. 2001, 167:40-47.
48. Stopa E.G., Gonzalez A., Chorsky R., Corona R.J., Alvarez J., Bird E.D., Baird A. Basic fibroblast growth factor in Alzheimer's disease. Biochem. Biophys. Res. Commun. 1990, 171:690-696.
49. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S., Ledermann B., Bürki K., Frey P., Paganetti P.A., Waridel C., Calhoun M.E., Jucker M., Probst A., Staufenbiel M., Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:13287-13292.
50. Tatebayashi Y., Iqbal K., Grundke-Iqbal I. Dynamic regulation of expression and phosphorylation of tau by fibroblast growth factor-2 in neural progenitor cells from adult rat hippocampus. J.Neurosci. 1999, 19:5245-5254.
51. Timmer M., Cesnulevicius K., Winkler C., Kolb J., Lipokatic-Takacs E., Jungnickel J., Grothe C. Fibroblast growth factor (FGF)-2 and FGF receptor 3 are required for the development of the substantia nigra, and FGF-2 plays a crucial role for the rescue of dopaminergic neurons after 6-hydroxydopamine lesion. J.Neurosci. 2007, 27:459-471.
52. Turner C.A., Clinton S.M., Thompson R.C., Watson S.J., Akil H. Fibroblast growth factor-2 (FGF2) augmentation early in life alters hippocampal development and rescues the anxiety phenotype in vulnerable animals. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:8021-8025.
53. Tuszynski M.H., Thal L., Pay M., Salmon D.P., U H.S., Bakay R., Patel P., Blesch A., Vahlsing H.L., Ho G., Tong G., Potkin S.G., Fallon J., Hansen L., Mufson E.J., Kordower J.H., Gall C., Conner J. Aphase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med. 2005, 11:551-555.
54. Villa A., Latasa M.J., Pascual A. Nerve growth factor modulates the expression and secretion of beta-amyloid precursor protein through different mechanisms in PC12 cells. J.Neurochem. 2001, 77:1077-1084.
55. Wagner J.P., Black I.B., DiCicco-Bloom E. Stimulation of neonatal and adult brain neurogenesis by subcutaneous injection of basic fibroblast growth factor. J.Neurosci. 1999, 19:6006-6016.
56. Wahlberg L.U., Lind G., Almqvist P.M., Kusk P., Tornøe J., Juliusson B., Söderman M., Selldén E., Seiger Å., Eriksdotter-Jönhagen M., Linderoth B. Targeted delivery of nerve growth factor via encapsulated cell biodelivery in Alzheimer disease: a technology platform for restorative neurosurgery. J.Neurosurg. 2012, 117:340-347.
57. Werner S., Unsicker K., von Bohlen und Halbach O. Fibroblast growth factor-2 deficiency causes defects in adult hippocampal neurogenesis, which are not rescued by exogenous fibroblast growth factor-2. J.Neurosci. Res. 2011, 89:1605-1617.
58. Wong G.T., Manfra D., Poulet F.M., Zhang Q., Josien H., Bara T., Engstrom L., Pinzon-Ortiz M., Fine J.S., Lee H.J., Zhang L., Higgins G.A., Parker E.M. Chronic treatment with the γ-secretase inhibitor LY-411,575 inhibits β-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J.Biol. Chem. 2004, 279:12876-12882.
59. Woodbury M.E., Ikezu T. Fibroblast growth factor-2 signaling in neurogenesis and neurodegeneration. J.Neuroimmune Pharmacol. 2014, 29:92-101.
60. Wu D., Pardridge W.M. Neuroprotection with noninvasive neurotrophin delivery to the brain. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:254-259.
61. Yoshimura S., Takagi Y., Harada J., Teramoto T., Thomas S.S., Waeber C., Bakowska J.C., Breakefield X.O., Moskowitz M.A. FGF-2 regulation of neurogenesis in adult hippocampus after brain injury. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:5874-5879.
62. Yoshimura S., Teramoto T., Whalen M.J., Irizarry M.C., Takagi Y., Qiu J., Harada J., Waeber C., Breakefield X.O., Moskowitz M.A. FGF-2 regulates neurogenesis and degeneration in the dentate gyrus after traumatic brain injury in mice. J.Clin. Invest. 2003, 112:1202-1210.
63. Youmans K.L., Tai L.M., Kanekiyo T., Stine W.B., Michon S.C., Nwabuisi-Heath E., Manelli A.M., Fu Y., Riordan S., Eimer W.A., Binder L., Bu G., Yu C., Hartley D.M., LaDu M.J. Intraneuronal Aβ detection in 5xFAD mice by a new Aβ-specific antibody. Mol. Neurodegener. 2012, 7:8.
64. Zhang Y., Pardridge W.M. Neuroprotection in transient focal brain ischemia after delayed intravenous administration of brain-derived neurotrophic factor conjugated to a blood-brain barrier drug targeting system. Stroke 2001, 32:1378-1384.
65. Zhang Y., Tounekti O., Akerman B., Goodyer C.G., LeBlanc A. 17-β-Estradiol induces an inhibitor of active caspases. J.Neurosci. 2001, 21:RC176.
66. Zhong H., Voll R.E., Ghosh S. Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol. Cell. 1998, 1:661-671.